Intellia’s Phase 3 win for its in vivo CRISPR treatment is also accelerating planning for the regulatory timeline. Following the Phase 3 results, Intellia said it is racing toward an FDA rolling submission for lonvoguran ziclumeran, reflecting a shift from clinical readout to filing execution. The company’s emphasis on a single-dose, in-body editing approach continues to drive investor attention because it challenges prior in vivo gene-editing barriers tied to delivery and durability. For hereditary angioedema patients, the clinical signal—particularly the proportion of attack-free patients—sets up a potential pivotal moment in CRISPR commercialization. Regulators and payers will likely focus on manufacturing, long-term safety monitoring, and durability metrics as the submission progresses.